Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas.
Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas
J Nucl Med. 2019 Apr;60(4):459-465. doi: 10.2967/jnumed.118.213488. Epub 2019 Feb 7.
Intraoperative detection of tumors has had a profound impact on how cancer surgery is performed and addresses critical unmet needs in surgical oncology. Tumor deposits, margins, and residual cancer can be imaged through the use of fluorescent contrast agents during surgical procedures to complement visual and tactile guidance. The combination of fluorescent and nuclear contrast into a multimodality agent builds on these capabilities by adding quantitative, noninvasive nuclear imaging capabilities to intraoperative imaging. This review focuses on new strategies for the development and evaluation of targeted dual-labeled molecular imaging agents while highlighting the successful first-in-human application of this technique.
术中肿瘤检测对癌症手术的开展方式产生了深远的影响，满足了肿瘤外科领域的一些重大未满足需求。在手术过程中使用荧光对比剂可以对肿瘤沉积物、切缘和残留癌症进行成像，为视觉和触觉引导提供补充。荧光和核对比的结合为多模态造影剂，通过将定量、非侵入性核成像功能添加到术中成像中，进一步扩展了这些功能。本综述重点介绍了靶向双标记分子成像剂的开发和评估的新策略，同时强调了该技术的首次人体应用。
